in 1998 in the European Journal of Endocrinology
~15% average weight loss Common side effects: nausea, constipation, diarrhea Also shown to reduce cardiovascular and kidney disease risks in some patients Tirzepatide (Zepbound) A dual-action medication: GLP-1 + GIP Enhances insulin, appetite control, and fat metabolism Average weight loss: ~20% in clinical trials Weekly injection Similar GI side effects to semaglutide Retatrutide (Coming Soon) A triple-agonist: GLP-1 + GIP + glucagon receptor Early studies show weight loss approaching 25% Still in clinical trials
Maintaining steady blood sugar levels helps reduce the energy crashes often felt throughout the day
HSA and FSA accounts are accepted, and patients can add the Precision Peptide Genetic Test for $99 after their first month to unlock deeper personalization insights for future treatment decisions
Channels like MorelliFit often provide clear, practical demonstrations of handling and reconstitution techniques that can help solidify these best practices in a visual format
Important Notes: For women only, particularly those suffering from PCOS-related symptoms
